NASDAQ
19.08USD
-0.16 (-0.83%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.7B
P/E
—
EPS
—
Beta
0.37
52W range
11.91-25.59
Day range
19.01–19.85
Open
19.56
Prev close
19.24
Volume
1.9M
Avg volume
1.8M
Dividend
0.00
IPO
2016-03-02
https://www.marketbeat.com/instant-alerts/syndax-pharmaceuticals-q2-earnings-call-highlights-2026-08-04/ · 8/5/2026+1.00
https://seekingalpha.com/article/4922011-syndax-pharmaceuticals-inc-sndx-discusses-pipeline-expansion-and-next-phase-of-innovation-for · 7/15/2026+0.60
https://www.fool.com/coverage/filings/2026/03/21/this-biotech-stock-winner-is-up-72-but-a-usd4-million-trim-signals-a-slight-reset/ · 3/22/2026-0.20
https://www.fool.com/coverage/filings/2026/03/21/biotech-stock-up-72-sees-usd8-million-sale-but-here-s-why-one-fund-still-seems-bullish/ · 3/21/2026+0.60
https://www.fool.com/coverage/filings/2026/03/13/cancer-drug-maker-with-usd172-million-revenue-and-multiple-approved-therapies-draws-usd6-5-million-investment/ · 3/13/2026
https://www.reuters.com/legal/transactional/servier-buy-day-one-biopharmaceuticals-total-equity-value-25-billion-2026-03-06/ · 3/6/2026+1.00
https://www.globenewswire.com/news-release/2026/02/04/3232453/0/en/Syndax-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html · 2/4/2026+0.20
https://seekingalpha.com/article/4853975-syndax-pharma-stock-continuing-execution-in-aml · 12/17/2025+0.80
https://www.globenewswire.com/news-release/2025/12/03/3199315/0/en/Syndax-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html · 12/3/2025+0.00
https://seekingalpha.com/article/4848751-syndax-early-commercial-momentum-points-toward-strong-2026-growth · 11/30/2025+0.70
https://seekingalpha.com/article/4833527-syndax-expands-revuforj-approval · 10/27/2025+0.90
https://seekingalpha.com/article/4833320-syndax-pharmaceuticals-inc-sndx-discusses-fda-approval-of-revuforj-for-relapsed-or-refractory · 10/25/2025+1.00
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
